You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》嘉和生物(06998.HK)公开超购逾1,246倍 一手中签率仅3%
阿思达克 10-06 08:19
未录得盈利的生物科技股份嘉和生物(06998.HK)公布招股结果,公布发行1.2亿股,公开发售录超购1,246.52倍,冻结资金逾3,625.7亿元,国际发售项下初步提呈发售的发售股份已获超额认购,相当於国际发售项下初步可供认购发售股份总数约33倍。

经重新分配後,香港公开发售股份占全球发售股份总数上调至约50%。认购一手500股,中签率仅为3%,要认购180手即9万股才可稳获一手。每股上市价定於24元,为上限定价(原每股招股价介乎20.3元至24元),该股将於明日(7日)挂牌上市,联席保荐人、联席全球协调人、联席账簿管理人及联席牵头经办人为高盛、摩通及Jefferies。

据基石投资协议,基石投资者认购的发售股份数目共5,994万股,占紧随全球发售完成後已发行股本约12.46%。

嘉和生物预计集资净额26.94亿元,其中65%拟分配至主要产品,15%拟用於其管线中其他候选药物正在进行及计划进行的临床试验、适应症扩展及注册备案筹备,10%拟用於为其药物管线扩展提供资金,另外10%则用作一般企业用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account